Annual EBIT
-$132.55 M
-$72.65 M-121.30%
December 31, 2023
Summary
- As of February 7, 2025, TARS annual earnings before interest & taxes is -$132.55 million, with the most recent change of -$72.65 million (-121.30%) on December 31, 2023.
- During the last 3 years, TARS annual EBIT has fallen by -$105.55 million (-390.95%).
- TARS annual EBIT is now -9718.30% below its all-time high of -$1.35 million, reached on December 31, 2018.
Performance
TARS EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$21.10 M
+$10.18 M+32.54%
September 30, 2024
Summary
- As of February 7, 2025, TARS quarterly earnings before interest & taxes is -$21.10 million, with the most recent change of +$10.18 million (+32.54%) on September 30, 2024.
- Over the past year, TARS quarterly EBIT has increased by +$19.84 million (+48.46%).
- TARS quarterly EBIT is now -296.98% below its all-time high of $10.71 million, reached on March 31, 2021.
Performance
TARS Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$128.11 M
+$17.22 M+11.85%
September 30, 2024
Summary
- As of February 7, 2025, TARS TTM earnings before interest & taxes is -$128.11 million, with the most recent change of +$17.22 million (+11.85%) on September 30, 2024.
- Over the past year, TARS TTM EBIT has increased by +$4.56 million (+3.43%).
- TARS TTM EBIT is now -20138.86% below its all-time high of -$633.00 thousand, reached on September 30, 2019.
Performance
TARS TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
TARS EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -121.3% | +48.5% | +3.4% |
| 3 y3 years | -390.9% | +48.5% | +3.4% |
| 5 y5 years | -9718.3% | +48.5% | +3.4% |
TARS EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -862.4% | at low | -305.9% | +48.5% | -897.8% | +11.8% |
| 5 y | 5-year | -2983.9% | at low | -297.0% | +48.5% | -7361.4% | +11.8% |
| alltime | all time | -9718.3% | at low | -297.0% | +48.5% | <-9999.0% | +11.8% |
Tarsus Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$21.10 M(-32.5%) | -$128.11 M(-11.8%) |
| Jun 2024 | - | -$31.28 M(-10.1%) | -$145.33 M(+0.4%) |
| Mar 2024 | - | -$34.78 M(-15.0%) | -$144.69 M(+9.1%) |
| Dec 2023 | -$132.55 M(+121.3%) | -$40.94 M(+6.8%) | -$132.67 M(+26.8%) |
| Sep 2023 | - | -$38.32 M(+25.1%) | -$104.66 M(+18.6%) |
| Jun 2023 | - | -$30.64 M(+34.6%) | -$88.27 M(+40.5%) |
| Mar 2023 | - | -$22.76 M(+76.0%) | -$62.83 M(+4.7%) |
| Dec 2022 | -$59.90 M(+334.9%) | -$12.94 M(-41.0%) | -$59.99 M(-3.0%) |
| Sep 2022 | - | -$21.93 M(+321.8%) | -$61.85 M(+10.5%) |
| Jun 2022 | - | -$5.20 M(-73.9%) | -$55.95 M(+28.7%) |
| Mar 2022 | - | -$19.92 M(+34.6%) | -$43.47 M(+238.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$13.77 M(-49.0%) | -$14.80 M(-7.7%) | -$12.84 M(+34.9%) |
| Sep 2021 | - | -$16.04 M(-320.2%) | -$9.52 M(+162.8%) |
| Jun 2021 | - | $7.28 M(-32.0%) | -$3.62 M(-74.4%) |
| Mar 2021 | - | $10.71 M(-193.4%) | -$14.17 M(-47.5%) |
| Dec 2020 | -$27.00 M(+528.2%) | -$11.48 M(+13.2%) | -$27.00 M(+62.6%) |
| Sep 2020 | - | -$10.14 M(+210.8%) | -$16.61 M(+134.0%) |
| Jun 2020 | - | -$3.26 M(+54.1%) | -$7.10 M(+85.1%) |
| Mar 2020 | - | -$2.12 M(+95.4%) | -$3.83 M(+123.4%) |
| Dec 2019 | -$4.30 M(+218.4%) | -$1.08 M(+71.2%) | -$1.72 M(+171.2%) |
| Sep 2019 | - | -$633.00 K | -$633.00 K |
| Dec 2018 | -$1.35 M | - | - |
FAQ
- What is Tarsus Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Tarsus Pharmaceuticals?
- What is Tarsus Pharmaceuticals annual EBIT year-on-year change?
- What is Tarsus Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Tarsus Pharmaceuticals?
- What is Tarsus Pharmaceuticals quarterly EBIT year-on-year change?
- What is Tarsus Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Tarsus Pharmaceuticals?
- What is Tarsus Pharmaceuticals TTM EBIT year-on-year change?
What is Tarsus Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of TARS is -$132.55 M
What is the all time high annual EBIT for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals all-time high annual earnings before interest & taxes is -$1.35 M
What is Tarsus Pharmaceuticals annual EBIT year-on-year change?
Over the past year, TARS annual earnings before interest & taxes has changed by -$72.65 M (-121.30%)
What is Tarsus Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of TARS is -$21.10 M
What is the all time high quarterly EBIT for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals all-time high quarterly earnings before interest & taxes is $10.71 M
What is Tarsus Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, TARS quarterly earnings before interest & taxes has changed by +$19.84 M (+48.46%)
What is Tarsus Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of TARS is -$128.11 M
What is the all time high TTM EBIT for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals all-time high TTM earnings before interest & taxes is -$633.00 K
What is Tarsus Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, TARS TTM earnings before interest & taxes has changed by +$4.56 M (+3.43%)